Benchmark analyst Bruce Jackson lowered the firm’s price target on Humacyte (HUMA) to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte’s new shares for the target drop but believes the company’s customer base continues to build.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Positive Growth Prospects and Financial Stability Drive Buy Rating for Humacyte
- Humacyte Reports Q3 2025 Financial Results and Pipeline Progress
- Humacyte’s Earnings Call Highlights Growth and Challenges
- Humacyte’s Promising Growth and Strategic Collaborations Earn a Buy Rating
- Humacyte reports Q3 EPS (11c), consensus (15c)